A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
ApexOnco Front Page
Recent articles
The company is to test its KLK2-targeting pasritamig in a late-line setting.
Summit gatecrashes ASCO, but Harmoni shows no OS benefit and a large patient overlap.
The Breakwater study hits on overall survival with "unprecedented" data.
The combined company's MALT1 inhibitor has started phase 1.
Crunch time approaches for UroGen.
Meanwhile, Pfizer reckons it's found the right dose for its KAT6.
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
